Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- ILa | -.--% | -0.67% | -16.62% |
Mar. 14 | Top Premarket Gainers | MT |
Mar. 13 | Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 21.52M 8.09B |
---|---|---|---|---|---|
Net income 2024 * | -21M -7.89B | Net income 2025 * | -24M -9.02B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.26
x | P/E ratio 2025 * |
-1.77
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Newman
FOU | Founder | 68 | 21-02-23 |
Jeffrey Meckler
CEO | Chief Executive Officer | 57 | 21-08-02 |
Nir Sassi
DFI | Director of Finance/CFO | 48 | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
William Hayes
BRD | Director/Board Member | 58 | 21-08-02 |
Jeffrey Meckler
CEO | Chief Executive Officer | 57 | 21-08-02 |
Director/Board Member | 61 | 23-01-12 |
- Stock Market
- Equities
- INDP Stock
- NTEC Stock